Crossmark

Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study

Crossref DOI link: https://doi.org/10.1016/j.reumae.2020.10.006

Published Print: 2022-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Rosas, José

Liaño, Francisco Pasquau

Cantó, Mónica Llombart

Barea, José María Carrasco

Beser, Amparo Raga

Rabasa, José Tomás Algado

Adsuar, Francisco Martínez

Auli, Brian Vila

López, Isabel Fernández

Sainz, Ana María Garijo

Ramis, Pere Esquerdo

Pérez, Laura Ruiz

Rebollo, Mª Luisa Navarrete

Lorido, Raquel Hernández

Escolar, Laura Gómez
License Information

Text and Data Mining valid from 2022-03-01

stm-asf valid from 2022-03-01

stm-asf valid from 2022-03-01

stm-asf valid from 2022-03-01

stm-asf valid from 2022-03-01

stm-asf valid from 2022-03-01
More Information

This article is maintained by: Elsevier

Article Title: Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2020.10.006

Content Type: article

Copyright: © 2022 Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below